This page is in editorial and medical review. Content below is a scaffold — treat it as a preview, not guidance.
Common cancerBiomarker-drivenMulti-system care
Breast cancer your guide, one page.
A cancer that starts in the breast. This page tells you what it is, what to expect, and what to do next — in plain words.
Breast cancer covers several different diseases that all start in breast tissue. We've gathered the choices you'll face, what changes day-to-day, and the people who can help — all in one place.
Breast cancer is a heterogeneous group of malignancies classified by histology, hormone receptor and HER2 status, and stage. This guide walks through diagnosis, treatment options, and active research.
Breast cancer comprises invasive ductal carcinoma, invasive lobular carcinoma, in situ disease, and rarer histologies, stratified by ER/PR/HER2 expression and TNM stage. Multidisciplinary management is the standard of care.
Breast cancer is a molecularly stratified disease defined by ER/PR/HER2 expression, with intrinsic subtypes (luminal A/B, HER2-enriched, basal-like) carrying distinct prognostic and predictive signatures. Treatment paradigms now incorporate biomarker-guided systemic therapy and de-escalation strategies for low-risk disease.
This is a synthesized view — not a replacement for your care team.
Doctors sometimes tell you different things. This page shows what most people with breast cancer go through. Bring it to your next visit and ask which parts fit you.
It's common to get different timelines or advice from different doctors. The roadmap below reflects what guidelines generally recommend — your team may adjust the details based on you specifically. Bring questions, not conclusions.
Care for breast cancer often involves multiple specialists, and you may receive different guidance on sequencing. The roadmap reflects current consensus pathways from NCCN and society guidelines; individualized decisions remain with your clinical team.
Multidisciplinary management of breast cancer may yield variable recommendations on sequencing of surgery, systemic therapy, and radiation. The pathway below summarizes consensus pathways per NCCN Breast Cancer guidelines; final decisions should be individualized based on biology, stage, comorbidities, and patient preference.
Inter-clinician variation is common in breast cancer management, particularly in the borderline-stage and biomarker-discordant subgroups. The pathway aggregates NCCN, ASCO, and ESMO consensus; deviations are appropriate when multigene assay results, nodal yield, or patient factors warrant.
01 / Roadmap
Your first two years, mapped out.
A structured path from diagnosis through the choices that come next — so you have one place to look instead of three websites and four phone calls.
01
Week 0–2•You are here
Take a breath. Then build your team.
Find a doctor who specializes in breast cancer. Write down your questions. You don't need to decide anything today.
Identify a breast cancer specialist — often a breast surgeon and a medical oncologist. Start a notebook of questions. Almost nothing requires an immediate decision in the first two weeks.
Establish care at a breast cancer center or with a board-certified breast surgeon and medical oncologist. Compile imaging, pathology reports, and a question list. The initial weeks are for orientation and complete workup, not therapeutic decisions.
Referral to a multidisciplinary breast cancer program is recommended. Obtain copies of imaging on disc, the full pathology report (including receptor status pending or final), and any genetic counseling history. Initial visits focus on completing staging.
Referral to a multidisciplinary breast cancer program with capacity for genetic counseling, fertility consultation when relevant, and clinical trial review is recommended. Compile diagnostic imaging, core biopsy pathology with IHC, and family pedigree.
Questions to bringFind a specialist
02
Month 1–2
Complete your staging workup.
Your doctor will do more tests so they understand what kind of cancer it is and where it is. This is a starting picture.
Additional imaging, pathology results, and sometimes a genetic test fill in the picture. These aren't treatments — they're what your team needs to recommend a plan.
Workup typically includes hormone receptor and HER2 testing, sometimes breast MRI, and staging studies for higher-risk disease. Genetic counseling is recommended for patients meeting NCCN criteria.
Complete pathology with ER/PR/HER2 status, Ki-67 where used, and a multigene assay in eligible hormone-receptor-positive cases. Imaging stage is finalized per NCCN guidance. Germline testing per current criteria.
Pathologic characterization includes ER/PR/HER2 IHC with reflex FISH on equivocal cases, multigene recurrence assays (Oncotype DX, MammaPrint) in HR+/HER2- early-stage disease, and staging modalities calibrated to clinical stage. Germline panel testing per NCCN/ASCO criteria.
What each test doesHow to prep
03
Month 2–4
Build the treatment plan together.
You and your team look at the results and decide the order of surgery, medicine, and (sometimes) radiation.
Results from staging are reviewed in a tumor board or with your team. The plan combines surgery, systemic therapy (chemo, hormone therapy, or targeted drugs), and sometimes radiation. The order depends on biology and stage.
Multidisciplinary tumor board review yields a sequenced plan. Neoadjuvant therapy is increasingly favored in HER2+ and triple-negative disease; upfront surgery still applies in many HR+/HER2- early-stage cases.
Treatment sequencing reflects intrinsic subtype, stage, and patient factors. Neoadjuvant chemotherapy is standard in HER2+ and TNBC of cT1c+ or node-positive disease. HR+/HER2- disease often proceeds to upfront surgery with adjuvant systemic therapy guided by multigene assay.
Treatment sequencing is biology-driven: neoadjuvant therapy in HER2+ and TNBC enables pathologic-complete-response-guided adjuvant intensification (T-DM1, capecitabine, pembrolizumab); HR+/HER2- early-stage disease typically proceeds to upfront surgery with adjuvant endocrine therapy ± CDK4/6 inhibitor and chemotherapy informed by genomic assay.
Questions to askAbout neoadjuvant therapy
04
Month 6–24
Active treatment, then follow-up.
Treatment is intense at first, then settles into check-ups. Most check-ups are quick visits to make sure nothing's changed.
After surgery and any chemo or radiation, many people start years of hormone therapy or other long-term medicines. Follow-up visits become routine — usually every 6–12 months.
Adjuvant therapy duration ranges from months (chemotherapy, HER2-targeted) to years (endocrine therapy). Surveillance includes physical exam every 3–6 months for 5 years, then annually, with mammography per guidelines.
Adjuvant endocrine therapy commonly continues 5–10 years; HER2-targeted therapy completes at 1 year for most regimens. Survivorship care addresses surveillance, treatment-related toxicities, and risk-reduction strategies.
Extended adjuvant endocrine therapy decisions (5 vs 7–10 years) are individualized by recurrence risk and tolerance. Surveillance protocols emphasize clinical exam and mammography; routine systemic imaging or tumor markers are not recommended in asymptomatic patients.
Surveillance scheduleWhen to call your doctor
02 / What to expect
How this will actually affect your day.
Starting with the question most people care about most: what changes about real life. Harder topics are below, available when (and only when) you want them.
a
Day-to-day routines
Daily life stays the same for most people once treatment plans are set. Active chemo or surgery weeks are harder; in-between weeks usually feel normal.
Outside of active chemotherapy cycles or the weeks right after surgery, daily routines mostly hold. The biggest practical change is scheduling around treatment days, scans, and infusions.
Functional status is generally well preserved between active treatment cycles. Adjuvant endocrine therapy can introduce ongoing low-grade symptoms (hot flashes, joint stiffness) that are typically manageable.
Performance status decrements correlate primarily with active cytotoxic therapy cycles and the immediate postoperative period. Long-term endocrine therapy can produce arthralgia, vasomotor symptoms, and sexual side effects.
Patient-reported outcomes in adjuvant endocrine therapy cohorts show variable QoL impact driven primarily by arthralgia and vasomotor symptoms; targeted symptom management strategies are well-described and should be proactively offered.
b
Work & energy
Many people keep working through treatment. Some take time off during chemo weeks. Your team can help you plan.
Work continues for many people through endocrine therapy and radiation. Chemotherapy cycles often need short time off; recovery from surgery typically takes 2–6 weeks depending on the procedure.
Employment continuity is common outside active chemotherapy and the immediate postoperative window. Counsel patients on FMLA/disability options for treatment-heavy phases.
Occupational accommodations during active treatment phases reduce attrition and improve outcomes. Sustained work limitation outside active treatment is uncommon.
Workforce participation during adjuvant therapy is associated with improved psychosocial outcomes; structured accommodations during active phases enable continuity. Disability claims during long-term endocrine therapy are infrequent and should prompt symptom management review.
c
Family & relationships
Some breast cancers run in families. A genetic counselor can help your family decide who else might want to be tested.
Hereditary breast cancer accounts for roughly 5–10% of cases. Genetic counseling and testing — especially for BRCA1/2, PALB2, and other genes — can affect treatment decisions and inform family members.
Germline testing per NCCN criteria can guide surgical, surveillance, and systemic therapy decisions. Cascade testing of at-risk relatives is the standard next step when a pathogenic variant is identified.
Germline panel testing per current NCCN criteria identifies actionable variants in roughly 8–10% of breast cancer patients. Cascade testing extends benefit to relatives; reproductive options including PGT-M should be discussed when applicable.
Germline testing thresholds have expanded; panel testing identifies BRCA1/2, PALB2, ATM, CHEK2, and other moderate-to-high-penetrance variants with downstream implications for PARP inhibitor candidacy, contralateral risk-reduction, and cascade screening of relatives.
d
Mental load
Getting the diagnosis is the hardest part for most people. It usually gets easier once you have a plan.
The early uncertainty is often the hardest stretch. Anxiety typically eases once a treatment plan is in place. Many people benefit from talking with a counselor familiar with cancer.
Psychological adjustment is a recognized component of breast cancer care. Anxiety peaks at diagnosis and around surveillance scans ("scanxiety"); psychosocial oncology services improve outcomes.
Psychosocial morbidity is well-documented and increasingly integrated into multidisciplinary care. Screening for distress and proactive psychosocial referral are evidence-based.
Distress screening with validated tools (NCCN Distress Thermometer) and integrated psychosocial oncology services improve adherence, QoL, and selected oncologic outcomes per multiple cohort and randomized studies.
e
Travel & activities
Most activities are fine. Heavy lifting and travel right after surgery may need to wait a few weeks.
Most travel and exercise resumes after surgical recovery. During chemotherapy, immune suppression around the nadir warrants caution with large crowds and travel; resume activities between cycles.
Activity restrictions are time-limited around surgery (typically 2–4 weeks for lumpectomy, longer for mastectomy with reconstruction). Lymphedema precautions are recommended after axillary procedures.
Postoperative restrictions are procedure-specific. Lymphedema prevention strategies after axillary lymph node dissection are evidence-based. Travel during active chemotherapy is generally feasible with attention to nadir timing.
Lymphedema risk-reduction practices after axillary node dissection are evidence-based; structured exercise programs reduce both lymphedema incidence and chemotherapy-related fatigue per RCT data.
f
The visits themselves
You'll see a few different doctors — a surgeon, a cancer doctor, sometimes a radiation doctor. Keeping notes in one place helps.
Care involves multiple specialists. Multidisciplinary breast clinics or shared electronic records ease the friction; bringing a list of current medications and questions to each visit helps.
Multidisciplinary care models — concurrent or sequential visits with surgeon, medical oncologist, and radiation oncologist — reduce visit count and improve coordination metrics.
Multidisciplinary clinic models with same-day pathology review and integrated planning are associated with improved time-to-treatment and patient satisfaction in published cohorts.
Integrated multidisciplinary care models demonstrate improved time-to-treatment initiation, adherence to guideline-concordant care, and patient-reported coordination metrics; nurse navigator integration further reduces friction in published studies.
⚠ Sensitive content — statistics on outcomes
Most breast cancer found early is treated successfully. Numbers about how often the cancer comes back depend a lot on the type and stage. Your doctor can tell you what fits your situation.
Five-year survival for early-stage breast cancer is very high; advanced-stage disease has improved significantly with newer treatments but remains the area where progress is most needed. Population statistics aren't predictions for any one person.
Population-level five-year survival approaches 99% for localized disease and 86% for regional disease per SEER data; metastatic disease median survival has improved substantially in recent decades but remains significantly lower. Individual prognosis depends on biology and treatment response.
SEER 5-year relative survival: localized 99%, regional 86%, distant 31% (all stages combined, recent reporting cycle). Subtype-specific outcomes vary substantially: HER2+ and HR+/HER2- early-stage disease has excellent prognosis; TNBC and metastatic disease show wider variation.
SEER 5-year relative survival figures vary by subtype, stage, and treatment era. Modern HER2-targeted and CDK4/6 inhibitor regimens have shifted overall survival benchmarks in HER2+ and HR+/HER2- metastatic settings; molecular subtyping increasingly drives prognostic conversation. Cohort statistics should not be presented as individual predictions.
These numbers describe populations, not individuals. Your team can interpret them in the context of your specific situation.
03 / Medications
Treatments, standard and emerging.
Common medications people are typically on, plus newer therapies you may hear about. Tap any card to save it to your dashboard.
Tamoxifen
tamoxifen citrate
Standard
A daily pill that blocks the hormones that some breast cancers feed on. Used for many years to lower the chance the cancer comes back.
A selective estrogen receptor modulator (SERM). It blocks estrogen from feeding hormone-receptor-positive breast cancer cells. Common in both premenopausal and postmenopausal patients.
First-line endocrine therapy for premenopausal HR+ breast cancer; used in postmenopausal patients when aromatase inhibitors are contraindicated. Typical course 5–10 years.
SERM with mixed agonist/antagonist activity. Standard adjuvant endocrine therapy in premenopausal HR+ breast cancer; consideration in postmenopausal patients per individual factors. Monitor for endometrial changes and thromboembolic events.
Selective estrogen receptor modulator with tissue-specific agonist/antagonist activity. Adjuvant endocrine standard in premenopausal HR+ disease per NSABP B-14, ATLAS, and aTTom; extended duration (10 years) reduces recurrence in selected patients. Surveillance for endometrial pathology and venous thromboembolism is standard.
FormOral
FrequencyDaily
Approved1977
OTCNo
From trialYes
Aromatase inhibitors
anastrozole, letrozole, exemestane
Standard
Daily pills (for postmenopausal patients) that lower estrogen in the body. Used in hormone-positive breast cancer.
Aromatase inhibitors block the enzyme that makes estrogen outside the ovaries. They're the standard for postmenopausal HR+ patients; premenopausal patients use them with ovarian suppression.
AIs are first-line adjuvant endocrine therapy in postmenopausal HR+ breast cancer. Premenopausal patients require concurrent ovarian function suppression. Bone-density monitoring is standard.
Third-generation AIs (anastrozole, letrozole, exemestane) inhibit peripheral aromatase. Standard adjuvant therapy in postmenopausal HR+ disease per ATAC, BIG 1-98, and IES trials. Monitor BMD; manage arthralgia proactively.
Non-steroidal (anastrozole, letrozole) and steroidal (exemestane) AIs achieve ~98% estrogen suppression in postmenopausal patients. Long-term adjuvant data favor 5+ years; extended therapy decisions individualized by recurrence risk and tolerability. Bone-modifying agents indicated per BMD trajectory.
FormOral
FrequencyDaily
Approved1995–2005
OTCNo
From trialYes
Trastuzumab
trastuzumab
Standard
An infusion (or shot) for HER2-positive breast cancer. Made the outcomes for this type of cancer dramatically better.
A monoclonal antibody that targets HER2, a protein over-expressed in about 15–20% of breast cancers. Used in early-stage and metastatic HER2+ disease, typically with chemotherapy.
Standard backbone of HER2-targeted therapy. In early-stage HER2+ disease, typically completes 1 year of adjuvant therapy. In metastatic disease, used in multiple lines with various partners.
Humanized monoclonal antibody against HER2 extracellular domain. Pivotal in transforming HER2+ breast cancer outcomes. Cardiotoxicity monitoring (LVEF) is standard. Subcutaneous formulation available.
Anti-HER2 monoclonal antibody with effects via receptor signaling inhibition and antibody-dependent cellular cytotoxicity. Standard in adjuvant and metastatic HER2+ disease per HERA, BCIRG-006, and pivotal metastatic trials. Cardiotoxicity is the principal monitorable AE.
FormInfusion / Injection
FrequencyEvery 1–3 weeks
Approved1998
OTCNo
From trialYes
04 / Novel therapies
Newer options worth knowing about.
Recently approved treatments or therapies that started in trials and are now part of care. Most of what's standard today went through this same path.
Trastuzumab deruxtecan
fam-trastuzumab deruxtecan-nxki
Novel · 2019
A newer infusion for HER2-positive or HER2-low breast cancer that has spread. Came out of clinical trials and has changed how doctors treat this disease.
An antibody-drug conjugate: a HER2-targeted antibody attached to a chemotherapy payload, delivered specifically to cancer cells. Approved first for HER2+ disease, then expanded to HER2-low based on the DESTINY trials.
First antibody-drug conjugate to demonstrate efficacy in HER2-low metastatic breast cancer, expanding the addressable population. Used in later lines for HER2+ disease and second-line+ for HER2-low.
Antibody-drug conjugate combining trastuzumab with a topoisomerase I inhibitor payload via a cleavable linker. Practice-changing data from DESTINY-Breast03 (HER2+) and DESTINY-Breast04 (HER2-low). Monitor for interstitial lung disease.
Antibody-drug conjugate with high drug-to-antibody ratio and cleavable peptide linker enabling bystander effect. DESTINY-Breast03 established superiority over T-DM1 in HER2+ metastatic disease; DESTINY-Breast04 established a new category of HER2-low disease with treatment benefit. ILD remains the principal serious AE requiring close monitoring.
FormInfusion
FrequencyEvery 3 weeks
FDA Approval2019
From trialYes
A common misconception
Clinical trials aren't a last resort.
Many people think clinical trials are only for when nothing else works. That's not how they work. In most trials today, you still get the normal treatment — the trial just adds something on top. If the extra thing causes harm, the trial stops right away.
A common assumption is that clinical trials are an experimental gamble or a last resort. In modern breast cancer trials, this is rarely true. The standard design is: patients receive established standard of care, plus the investigational therapy. Trials are stopped immediately if harm signals emerge.
Contemporary trial design follows a standard-of-care-plus model. Patients are never assigned to substandard treatment. Safety monitoring boards halt trials at predefined harm thresholds.
Modern breast cancer trial architecture incorporates standard-of-care backbones with experimental arms, governed by DSMBs with predefined stopping rules. Equipoise requires no participant receive substandard care; placebo arms in active-disease settings are uncommon and ethically constrained.
Contemporary breast cancer trial design under ICH-GCP and FDA guidance enforces equipoise: experimental arms layer onto standard backbones, DSMBs enforce stopping rules at predefined toxicity or efficacy thresholds. The "last-resort" framing reflects mid-20th-century trial models, not current practice.
The medication above came out of a trial. So did tamoxifen, the aromatase inhibitors, and trastuzumab. Modern standard of care is the cumulative product of decades of breast cancer trials.
05 / Landmark trials
The trials that built the treatments you have today.
Every medication on your standard-of-care list started as a clinical trial. This is the short history of how the field arrived at modern care — and where it's heading next.
Why this matters
Trials aren't separate from "real" medicine — they are how real medicine gets made.
Every breast cancer treatment your doctor offers was once part of a clinical trial. The trials below are the big ones that changed how this disease is treated.
Reading these isn't about deciding to join a trial today. It's about understanding where today's breast cancer treatments came from — and why patients who participated in earlier trials are why current options exist.
Each entry below represents a pivotal trial whose results altered standard practice. Understanding this lineage clarifies how evidence moves from investigation into guideline-supported care.
The trials below represent registrational and paradigm-shifting studies that informed current NCCN and society guidelines for breast cancer.
These studies represent registrational trials and paradigm-shifting investigations that reshaped guideline-directed therapy in breast cancer.
1989
First-in-classPhase 3Practice-changing
NSABP B-14: Tamoxifen in node-negative HR+ breast cancer
The trial that showed tamoxifen helps prevent breast cancer from coming back.
Established that tamoxifen after surgery reduces recurrence in node-negative HR+ disease — the model for adjuvant endocrine therapy.
Pivotal trial demonstrating tamoxifen's adjuvant benefit in node-negative HR+ breast cancer; the foundation of decades of endocrine therapy practice.
Pivotal trial demonstrating disease-free survival benefit of adjuvant tamoxifen in node-negative ER-positive breast cancer; basis for FDA adjuvant indication.
Pivotal trial establishing adjuvant tamoxifen's recurrence-reduction benefit in node-negative ER-positive breast cancer (NSABP B-14); foundation for the modern adjuvant endocrine therapy paradigm and downstream extended-duration trials (ATLAS, aTTom).
What it tested
Patients with early hormone-positive breast cancer got either tamoxifen pills or no pills after surgery. Doctors followed them for years to see who did better.
Randomized 2,818 node-negative ER+ patients to 5 years of tamoxifen vs placebo after surgery. Followed for disease-free and overall survival.
Multicenter randomized trial of adjuvant tamoxifen (20 mg daily × 5 years) vs placebo in node-negative ER+ breast cancer after definitive surgery.
Multicenter, double-blind, randomized Phase 3 trial; 2,818 patients with node-negative ER+ breast cancer allocated to tamoxifen 20 mg daily × 5 years vs placebo following definitive surgery and radiation per local practice.
Multicenter, double-blind, placebo-controlled Phase 3 trial in 2,818 women with node-negative, ER+ early breast cancer, allocated to tamoxifen 20 mg daily × 5 years vs placebo post-definitive surgery and adjuvant radiation. Long-term follow-up published in extended-analysis reports.
What it changed
After this trial, hormone-positive breast cancer patients started getting tamoxifen routinely.
Tamoxifen became standard adjuvant therapy in node-negative ER+ disease, eventually extending to node-positive patients and other settings.
Established adjuvant endocrine therapy as the standard in HR+ early breast cancer; downstream trials extended duration (ATLAS, aTTom) and broadened indications.
Established 5-year adjuvant tamoxifen as standard in node-negative HR+ disease; FDA approval in this indication followed. Downstream ATLAS/aTTom trials supported extended duration in selected patients.
Established 5-year adjuvant tamoxifen as standard in node-negative HR+ early breast cancer; subsequent extended-duration trials (ATLAS, aTTom) supported 10-year duration in selected high-risk patients. Foundation for decades of endocrine therapy refinement.
Published source available on request
2005
First-in-classPhase 3Practice-changing
HERA: Adjuvant trastuzumab in HER2+ early breast cancer
The trial that showed trastuzumab dramatically helps HER2-positive breast cancer.
Established adjuvant trastuzumab as standard for HER2+ early breast cancer — one of the largest improvements in any cancer's outcome from a single drug.
Pivotal trial establishing 1-year adjuvant trastuzumab after chemotherapy as standard in HER2+ early breast cancer; transformed prognosis.
Registrational adjuvant trial demonstrating disease-free and overall survival benefit of 1-year trastuzumab in HER2+ early breast cancer; basis for FDA adjuvant approval.
Pivotal randomized Phase 3 trial demonstrating substantial DFS and OS benefit of 1-year adjuvant trastuzumab in HER2+ early breast cancer (HR for DFS ~0.54 in initial reporting); foundation for the modern HER2-targeted adjuvant paradigm.
What it tested
Patients with HER2-positive breast cancer who had already had chemo got either a year of trastuzumab or nothing. The trastuzumab group did dramatically better.
Randomized 5,090 HER2+ early breast cancer patients after chemotherapy to 1 year of trastuzumab, 2 years of trastuzumab, or observation. Disease-free survival was the primary endpoint.
Three-arm randomized comparison of observation vs 1-year vs 2-year adjuvant trastuzumab following standard chemotherapy in HER2+ early breast cancer.
Multicenter, randomized Phase 3 trial; 5,090 patients with HER2+ early breast cancer allocated post-chemotherapy to observation, 1-year, or 2-year adjuvant trastuzumab. Primary endpoint: disease-free survival.
Multicenter, randomized, open-label Phase 3 trial in 5,090 HER2+ early breast cancer patients post-chemotherapy, randomized to observation, 1-year, or 2-year adjuvant trastuzumab. Primary endpoint DFS; subsequent analyses established 1-year as optimal duration.
What it changed
After this trial, every HER2-positive breast cancer patient gets trastuzumab as part of standard treatment.
Trastuzumab became standard adjuvant therapy in HER2+ early breast cancer, transforming the prognosis of this subtype.
Established 1-year adjuvant trastuzumab as the standard of care; subsequent trials refined chemotherapy partners and dual HER2-targeting strategies.
Established 1-year adjuvant trastuzumab as standard in HER2+ early breast cancer; FDA approval and incorporation into NCCN/ASCO guidelines followed. Downstream trials (APHINITY) added dual HER2 blockade in selected patients.
Established 1-year adjuvant trastuzumab as standard of care in HER2+ early breast cancer; downstream APT, APHINITY, KATHERINE, and ExteNET trials refined regimen selection by risk stratum and post-neoadjuvant residual disease.
KATHERINE: T-DM1 after residual disease post-neoadjuvant therapy
The trial that gave patients with HER2-positive breast cancer a second-line option when chemo + trastuzumab didn't clear the cancer before surgery.
Established T-DM1 (an antibody-drug conjugate) as adjuvant therapy for HER2+ patients who had residual disease after neoadjuvant treatment — a major new option for the highest-risk group.
Pivotal trial establishing T-DM1 as adjuvant therapy in HER2+ breast cancer with residual disease after neoadjuvant chemotherapy + trastuzumab.
Registrational Phase 3 trial demonstrating ~50% reduction in invasive disease recurrence with adjuvant T-DM1 vs trastuzumab in patients with residual disease after neoadjuvant HER2-directed therapy.
Pivotal Phase 3 trial (KATHERINE/NCT01772472) demonstrating ~50% reduction in invasive disease-free survival hazard with adjuvant T-DM1 vs trastuzumab in HER2+ residual-disease patients post-neoadjuvant therapy; established post-neoadjuvant adjuvant escalation paradigm.
What it tested
Patients with HER2+ breast cancer who still had cancer left after chemo + trastuzumab before surgery were randomly assigned to either keep getting trastuzumab or switch to T-DM1.
Randomized 1,486 HER2+ patients with residual disease after neoadjuvant chemotherapy + HER2-directed therapy to either continued trastuzumab or T-DM1 for 14 cycles.
Randomized Phase 3 trial of adjuvant T-DM1 vs trastuzumab in HER2+ early breast cancer with residual invasive disease after neoadjuvant chemotherapy + HER2 therapy. Primary endpoint: invasive disease-free survival.
Multicenter, randomized, open-label Phase 3 trial; 1,486 patients with HER2+ early breast cancer and residual invasive disease post-neoadjuvant chemo + HER2 therapy allocated to T-DM1 × 14 cycles vs trastuzumab × 14 cycles.
Multicenter, randomized, open-label Phase 3 trial in 1,486 HER2+ early breast cancer patients with residual invasive disease after neoadjuvant chemotherapy + HER2-targeted therapy, randomized to T-DM1 × 14 cycles vs trastuzumab × 14 cycles. Primary endpoint: invasive DFS (HR ~0.50).
What it changed
After this trial, patients with HER2+ breast cancer who had cancer remaining after chemo + trastuzumab started getting T-DM1 instead. Their chance of recurrence dropped.
T-DM1 became standard adjuvant therapy for HER2+ patients with residual disease — a major upgrade for the highest-risk HER2+ group.
Established T-DM1 as the adjuvant standard for HER2+ residual-disease patients, formalizing the post-neoadjuvant adjuvant-escalation paradigm.
Established T-DM1 as the adjuvant standard for HER2+ residual-disease patients per NCCN and ASCO guidelines; redefined post-neoadjuvant adjuvant pathway.
Established post-neoadjuvant adjuvant escalation as a paradigm in HER2+ breast cancer (T-DM1 for residual disease per KATHERINE); analogous strategies subsequently evaluated in TNBC (CREATE-X, OlympiA for BRCA+) and HR+ disease.
Patient communities, foundations, and clinical centers that focus on this condition. Save any of these to keep them on your dashboard.
Patient Foundation
Breast Cancer Research Foundation (BCRF)
National foundation funding breast cancer research and offering patient education resources. Searchable database of research priorities and downloadable plain-language explainers.
Active patient-to-patient forum. Members discuss specific treatments, side effects, insurance navigation, and daily life with breast cancer across stages and subtypes.
NCI-designated cancer centers offer multidisciplinary breast cancer programs with surgical, medical, and radiation oncology in one place. Many accept second opinions and offer virtual consults.
Free directory of genetic counselors specializing in hereditary cancer. They help you decide about testing, navigate family conversations, and plan reproductive options when relevant.
Directory of in-person and virtual mental health support specifically for people with cancer. Sliding-scale options and caregiver-specific programming.
This page is educational, not medical advice. Talk with your care team about decisions that apply to you. If something feels urgent, contact your doctor — or, for emergencies, call your local emergency number.
